Uses
Tebipenem is an orally available carbapenem antibiotic, shows broad-spectrum activity against Gram-positive and -negative bacteria, except for Pseudomonas aeruginosa.
Biological Activity
tebipenem is an orally available carbapenem antibiotic. tebipenem is active against a panel of clinical isolates from a variety of bacterial species (mic50s ≤ 0.0039 ~ 8 μg/ml), including methicillin-resistant strains of staphylococcus aureus (s. aureus) and staphylococcus epidermidis (s. epidermidis), as well as penicillin-resistant streptococcus pneumoniae (s. pneumonia). tebipenem also inhibits β-lactamase in a time- and concentration-dependent manner. tebipenem pivoxil, a derivative of tebipenem, has been under development as the first orally available carbapenem antibiotic for the treatment of respiratory and otolaryngological infections caused by drug-resistant s. pneumonia in pediatric patients.1. hazra s, xu h, blanchard js. tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from mycobacterium tuberculosis. biochemistry, 2014, 53(22): 3671-3678.2. fujimoto k, takemoto k, hatano k, et al. novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. antimicrobial agents and chemotherapy, 2013, 57(2): 697-707.
References
[1] Hazra S, et al. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry. 2014 Jun 10;53(22):3671-8 DOI:
10.1021/bi500339j[2] Seenama C, et al. In vitro activity of tebipenem against Burkholderia pseudomallei. Int J Antimicrob Agents. 2013 Oct;42(4):375. DOI:
10.1016/j.ijantimicag.2013.06.016[3] Li H, et al. In vitro antibacterial activities of two novel oral antibiotics, tebipenem and cefditoren, and other comparators against community-acquired respiratory tract infection-associated bacterial pathogens: A multicentre study in China. Int J Antimicrob Agents. 2014 Jan;43(1):92-3. DOI:
10.1016/j.ijantimicag.2013.09.009
